Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, with a net profit excluding non-recurring gains and losses estimated between -90.56 million and -74.09 million yuan, and operating revenue projected to be between 198.31 million and 242.38 million yuan [1] Group 1 - During the reporting period, the company's production and operational activities were normal, and it actively engaged in various marketing and market exploration efforts, resulting in slight growth in sales revenue and volume of the product Su Tai [1] - The revenue from the product Shutaqing decreased due to external environment and industry policy factors; the company is exploring multiple channels for the Shutaqing product market and focusing on expanding the marketing efforts for polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shusitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shuyi Qing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shuchang Qing)" [1] - The company expects non-recurring gains and losses for the year 2025 to be approximately 4.75 million yuan, with specific data to be disclosed in the 2025 annual report [1]

Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, indicating a challenging financial outlook for the upcoming year [1] Financial Performance - The company anticipates a net profit excluding non-recurring gains and losses to range from -90.56 million to -74.09 million yuan for 2025 [1] - Projected operating revenue for the same period is estimated to be between 198.31 million and 242.38 million yuan [1] Business Operations - During the reporting period, the company's production and operational activities were normal, with a slight increase in sales revenue and volume for the product Su Tai [1] - The revenue from the product Shutaqing has decreased due to external environmental factors and industry policies, prompting the company to explore multiple channels for market expansion [1] Product Development - The company is focusing on marketing efforts for its polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shu Sitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shu Yiqing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shu Changqing)" [1] Non-recurring Gains and Losses - The company expects non-recurring gains and losses for 2025 to be approximately 4.75 million yuan, with specific figures to be disclosed in the annual report [1]

Core Viewpoint - Shuyatong has reported a reduction in net loss for 2024 due to significant cuts in R&D expenses, but the company has not achieved profitability and has recorded net losses for five consecutive years [1][4]. Financial Performance - In 2024, Shuyatong achieved operating revenue of approximately 325 million yuan, a decrease of 10.81% compared to the previous year [2]. - The net profit attributable to shareholders was approximately -144.84 million yuan, an improvement from -398.89 million yuan in the previous year, reflecting a 63.69% reduction in loss [2]. - The cash generated from operating activities was -63.68 million yuan, showing a 72.11% improvement from -228.32 million yuan in the previous year [2]. R&D and Product Sales - The company significantly reduced its R&D investment by over 60%, with R&D expenses dropping from 448 million yuan in the previous year to 162 million yuan in 2024 [3]. - The number of R&D personnel decreased from 122 in 2023 to 104 in 2024, down from 262 in 2022 [4]. - Major products saw a decline in sales revenue: Shutaqing generated 179 million yuan (55.16% of total revenue, down 8.2% year-on-year), and Sutai Sheng generated 134 million yuan (41.21% of total revenue, down 17.3% year-on-year) [3]. Strategic Considerations - Experts suggest that pharmaceutical companies facing continuous losses should rationally plan R&D projects, focus resources on key product development, and enhance internal management to optimize costs [4]. - Collaborations with other companies and research institutions are recommended to share resources, reduce costs, and accelerate R&D progress [4].